ACAD Q1 2025 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$244M+18.7% YoY

Gross Profit

$224M91.7% margin

Operating Income

$19M7.9% margin

Net Income

$19M7.8% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

-5.9%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

-$79M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$367M

Stockholders' Equity

$765M

Cash & Equivalents

$218M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$244M	$206M	+18.7%
Gross Profit	$224M	$183M	+22.4%
Operating Income	$19M	$15M	+26.8%
Net Income	$19M	$17M	+14.7%